The Challenge of Change - Managing Excipients Control
Colorcon
| « Previous month | Next month » |
Jerusalem-based Yissum has formed a spin-off company Nanolymf, which will be dedicated to advancing a nanotechnology controlled-release drug delivery platform.
In-PharmaTechnologist.com brings you a selection of recent headlines from around the pharmaceutical manufacturing industry.
FMC BioPolymer is to expand its microcrystalline cellulose (MCC) production in a bid to meet demand for the company's excipients.
Consort Medical's UK operations may be in line for more job losses as further collateral damage from Pfizer's withdrawal of Exubera from the market.
Enzo Life Sciences has signed a letter of intent to acquire Belgian life science tools distributor 10P's BVBA for an undisclosed amount.
LabTechnologist.com brings you a round up of the latest product news and releases from Agilent, Caliper, Grabner, Micronic, Millipore, Torrey Pines and Warner.
US researchers have developed a new biochip technology that could dramatically reduce the need for animal testing during drug development safety studies.
France-based Flamel Technologies and Merck Serono have shook hands on a new €2m ($2.9m) deal which would see Flamel's Medusa technology used to develop an extended-release profile of an undisclosed therapeutic protein.
PharmEng's subsidiary Keata Pharma is the new owner of Pfizer's manufacturing facility in Arnprior, Canada, which the drug giant has been trying to pass on for over a year.
US researchers have shown that 2D NMR (nuclear magnetic resonance) experiments can greatly enhance the ability of metabolic profiling to quantify disease identification and progression.
Scientists have discovered a potential new drug target that will prick up the ears of sportsmen and athletes alike. Not that this is an performance-enhancing drug; instead, it could help athletes recover from injury more quickly.
Microarray expert Affymetrix is to buy molecular biology reagent firm USB Corporation for $75m (€52m) in a bid to accelerate the development of new genetic analysis tools.
LabTechnologist.com brings you a round up of recent industry news, with developments at Agilent, Bruker BioSpin, EMD Chemicals, Gene Logic, Paraytec and Thermo Fisher Scientific.
BioTimes' subsidiary, Embryome Sciences, is planning to build a relational database that will help identify the hundreds of cell types that can be made from human and mouse embryonic stem cells.
UK-based William Ransom & Son has a shaky future ahead following a disappointing and unacceptable six-month financial report, compounded by a suspension of the companys manufacturing license.
Biopartners has terminated its supply agreement with The Medical House because of a go-slow in receiving functional drug delivery devices.
Eli Lilly, Shire, Pregis, and Eisai have all had people on the move in the world of pharmaceutical manufacturing.
Affymetrix has launched a new analysis tool for determining genetic variations in whole-genome association and cytogenetic studies that is up to 10 times more sensitive than competing platforms.
Siegfried has signed a $27.7m contract with Arena Pharmaceuticals to manufacture Arena's Phase III oral obesity drug candidate lorcaserin hydrochloride.
Eli Lilly has handed over the manufacturing reins of the antibiotic Seromycin to the Chao Centre for Industrial Pharmacy and Contract Manufacturing.
Harvard Bioscience has rejected an unsolicited acquisition offer from Skystone Advisors to acquire all outstanding shares of common stock in the life science tools and instrument manufacturer.
Advances in the pharmaceutical industry are expected to have an impact on pharmaceutical excipients within the next decade, a new report claims.
Pronova BioPharma and FMC Corporation have signed a license and development agreement to develop products using an alginate-based capsule technology.
Patheon has finally revealed its plans to tackle the ongoing problems it has been facing with its Puerto Rican operations, which are draining the firm of profitability.
Any link between the antiviral Tamiflu and neuropsychiatric problems is inconclusive, according to the Japanese Government.
Curiox Biosystems has developed a miniaturisation platform that enables cheaper and more efficient bioassays to be conducted, potentially slashing the costs of life science and drug discovery research.
Merck has been hit with a contamination threat prompting the recall of a million of its childhood Hib vaccines across the US, right alongside the Canadian suspension of its MMR vaccine.
In-PharmaTechnologist.com brings you a selection of recent headlines from around the pharmaceutical manufacturing industry.
Novozymes and Millipore are to supply animal-free cell culture supplements to the biopharmaceutical industry.
LabTechnologist.com brings you a round-up of new product releases from Applied Biosystems, Bio-Rad, Carl Zeiss, Hilden, Hoefer, Porvair, Thermo Fisher Scientific and Warner Instruments.
Novartis is to sever a further 2,500 jobs as part of a new initiative aimed to 'improve competitiveness in a dynamically changing healthcare environment'.
US researchers have developed a fast and inexpensive protein biomarker detection device that could simplify disease diagnosis and aid in following disease progression in drug trials.
In-PharmaTechnologist.com brings you an update of pharmaceutical patent litigations.
The first steps in tightening the safety controls on the pharmaceutical ingredients imported to the US from China have been taken following months of negotiations between the regulatory bodies of the two countries.
BioWa and Lonza are joining forces to develop a new technology platform to produce more potent antibodies with enhanced cell-killing powers.
NNE Pharmaplan has won a contract with Pronova BioPharma to build the company's new pharma production facility in Kalundborg, Denmark.
Invitrogen has exclusively licensed 'click chemistry' technology from Harvard University that greatly simplifies the fluorescent-labelling of biomolecules for use in proliferation assays.
The repercussions of Pfizer's dramatic Exubera exit are finally filtering through to West Pharmaceutical Services, with the company preparing to restructure its affected Tech Group contract manufacturing unit.
Vyteris, Sciele Pharma, Nektar Therapeutics, Fundamental Applied Biology and Artes Medical have all had people on the move in the world of pharmaceutical manufacturing.
Researchers have developed a miniature synchrotron that could enable researchers to conduct protein crystallography experiments in their own university and 'revolutionise the way science is done'.
Merck Serono intends to forge ahead with severing its investment in diabetes and either sell or partner out its existing research and development (R&D) activities in this field, which it no longer feels able to compete in effectively.
LabTechnologist.com brings you a periodic update of recent industry news with developments at EMD Chemicals, MicroCal, Oxford Gene Technology, Protagen, Syrris and Varian.
Microscopy expert-Carl Zeiss has licensed a new fluorescence microscopy technique that enables scientists to determine the precise intracellular location of proteins of interest.
GE Healthcare and Novavax have a vision - a state-of-the-art pandemic influenza vaccine manufacturing facility solution with the ability to produce vaccines quickly, which can be marketed as a product to international countries.
The latest twist in Roche's long-running bid to acquire diagnostics expert Ventana has seen the pharma giant announce it intends to elect directors to Ventana's board at its next AGM (annual general meeting).
Eli Lilly is the latest big pharma company to signal plans of a vigorous commitment to outsourcing in a bid to prevent its fortunes fading.
Hikma has ticked another pharma firm off its shopping list as it acquires the Arab Pharmaceutical Manufacturing Company (APM) for $163.6m.
Transport Pharmaceuticals has been named the 2007 North American Technology Innovation of the Year Award winner in electrokinesis-enabled drug delivery.
Puerto Rico is making a concerted effort to attract biologic investment dollars onto the island as it falls foul of a retreat from pharma firms seeking solid dose manufacturing.
Japanese drugmaker Eisai has agreed to buy US biopharma firm MGI Pharma for $3.9bn (€2.7bn) in a bid to expand its US presence and strengthen its oncology pipeline.
Vetter, New England Peptide, Urigen Pharmaceuticals, Servac, and Patheon have all recently announced contract manufacturing news.
In-PharmaTechnologist.com brings you a selection of recent headlines from around the pharmaceutical manufacturing industry.
Separations expert Millipore is collaborating with Rohm and Haas Company to develop new high-performance chromatography products for use in biopharmaceutical manufacturing.
UK-based William Ransom & Son has been advised to voluntarily recall certain products following a false contamination scare at its Witham, Essex, facility.
UK researchers have published results that show that microfluidic devices can provide robust quantitative pharmacological information from low numbers of single cells.
LabTechnologist.com brings you a periodic round up of new product releases from Carl Zeiss SMT, Genetix, Ludesi, Millipore, Nikon, Olympus and Wiley-VCH.
A new genetic identity test that can be used to confirm the breed and origin of meat from farm animals has been developed to enable complete meat traceability.
DSM Anti-Infectives has signed up India's Arch Pharmalabs in a multi-year contract to manufacture generic active pharmaceutical ingredients (APIs).
Bristol-Myers Squibb (BMS) has finally detailed its plans to trim the fat and save cash, months after first revealing that big changes would be on the cards.
Sanofi-Aventis has opened its first Asian research and development centre in Goa, India, signalling its ambition to further tap in to this region's budding pharma scene.
Abbott is to shut its doors on its Galway, Ireland, facility - taking 500 jobs with it - as the market moves into murky waters over the future of vascular stents.
LabTechnologist.com brings you its periodic round up of industry news, with developments at Agilent, Beckman Coulter, Biolytix, Knome, Millipore, Nanogen and Qiagen.
Pharmaceutical Profiles, H.D. Smith, Consort Medical, Questcor Pharmaceuticals, and Sunesis Pharmaceuticals have all had people on the move in the world of pharmaceutical manufacturing.
Luminex has expanded its range of FlexmiR miRNA assays with the addition of user-customisable panels that will enable researchers to study only those miRNAs they are interested in.
The combination products market is zooming ahead, requiring the need to address regulatory challenges, an author of a white paper says.
Arius Research and Avid Bioservices have joined forces in the manufacturing and development of an anticancer antibody.
Canadian researchers have devised a method of extracting the complete proton NMR (nuclear magnetic resonance) spectra for a component of a mixture without the need for physical separation.
Bruker BioSciences is to acquire the affiliated, but privately-held Bruker BioSpin group for $914m (€620m) in a bid to expand its distribution capabilities and increase its customer base.
Paraytec has been chosen to lead a £1m (€1.4m) consortium project to develop new analytical instruments that will detect aggregation in biopharmaceutical processing.
Medgenics' Biopump could be the solution to the issues surrounding protein therapy and is set to take on the $51bn US biopharmaceutical market after raising £3.28m ($6.76m) in funding in its Initial Public Offering.
Denmark-based CMC Biopharmaceuticals has snapped up Eli Lilly's recently acquired biologics facility for an undisclosed amount.
Gene expression analysis expert Exiqon is to pay up to $45m (€30.7m) for diagnostics company Oncotech as a first step towards becoming a world leading miRNA diagnostic manufacturer.
Glenmark is one of a handful of pharma firms in India pushing forward a preclinical programme as a priority.
Boehringer Ingelheim has completed a hefty makeover of its biopharmaceutical production plant in Biberach, Germany.
Spanish firm Almirall is working on a new chronic obstructive pulmonary disease (COPD) treatment combined with a hi-tech easy use inhaler, creating what it hopes will be another competitive product from its in-house pipeline.
Sanofi-Aventis recently admitted it needed to increase the number of biotech compounds in its pipeline and now, true to its word, the French pharma heavyweight has signed a big antibody deal with US biotech Regeneron.
Pfizer is looking to Asia for both R&D and manufacturing outsourcing and to help it cut costs in a bid to mitigate the effects of patent expiries and competition from generic drugs.
| « Previous month | Next month » |